发明名称 Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions
摘要 Disclosed herein are compounds of formula (I); and therapeutic methods of treatment with compounds of formula (I), wherein L1, L2, L4, R1, R4, R5, R6, and s are as defined in the specification. Compounds of formula (I) are EP4 agonists useful in the treatment of glaucoma, neuropathic pain, and related disorders.
申请公布号 US9180116(B2) 申请公布日期 2015.11.10
申请号 US201314415506 申请日期 2013.07.19
申请人 Cayman Chemical Company, Inc. 发明人 Barrett Stephen Douglas;Ciske Fred Lawrence;Colombo Joseph Michael;Endres Gregory William;Germain Bradlee David;Kornilov Andriy;Kramer James Bernard;Uzieblo Adam;Maxey Kirk M.
分类号 C07D207/26;A61K31/4015;A61K31/4025;C07D409/06 主分类号 C07D207/26
代理机构 Brinks Gilson & Lione 代理人 Brinks Gilson & Lione
主权项 1. A compound of formula (Ia)or a pharmaceutically acceptable salt thereof, wherein: L1 is a) C3-C7alkylene, C3-C7alkenylene, or C3-C7alkynylene, wherein the C3-C7alkylene, C3-C7alkenylene, or C3-C7alkynylene are each optionally substituted with 1, 2, 3, or 4 fluoro substituents;b) —(CH2)t-G-(CH2)p—; wherein t is 0, 1, or 2, p is 0, 1, 2, or 3, and t+p=0, 1, 2, 3, or 4; orc) —(CH2)n-G1-(CH2)p—, —(CH2)n-G2-(CH2)p—, —(CH2)n—C≡C-G2-, or —(CH2)n—C(R13)═C(R13)-G2-, wherein n is 1, 2, 3, 4, or 5, p is 0, 1, 2, or 3, and n+p=1, 2, 3, 4, 5, or 6; G is G1 is O, C(O), S, S(O), S(O)2, or NR8; wherein R8 is H, C1-C1 alkyl, or C1-C4alkylcarbonyl; G2 iswherein G2 is optionally substituted with 1, 2, or 3 substituents selected from the group consisting of C1-C4alkyl, C1-C3haloalkyl, cyano, halogen, C1-C3alkoxy, and C1-C3haloalkoxy; R1 is COOR10, CONR10R11, CH2OR10, SO3R10, SO2NR10R11, PO(OR10)2, or tetrazol-5-yl; R10 is H, C1-C4 alkyl, or aryl; R11 is H, C1-C4 alkyl, COR12, OR10, or SO2R12; R12 is C1-C4 alkyl; R13, at each occurrence, is independently H or C1-C4alkyl; L4 is —C(R2)2—C(R3)2—, —C(R2)═C(R3)—, orwherein R2 and R3 are each H, CH3, fluoro, or chloro; L2 is —CH2— or a bond; R4 and R5 are each independently H, F, CF3, or C1-C4 alkyl; or R4 and R5 together with the carbon to which they are attached form a C3-C5 cycloalkyl, R6 is aryl, heteroaryl, C3-C10alkyl, C3-C10alkenyl, C3-C10alkynyl, C3-C10haloalkyl, C3-C10haloalkenyl, C3-C10haloalkynyl, or L3-R7; wherein the aryl and heteroaryl are optionally substituted with 1, 2, 3, or 4 substituents selected from the group consisting of C1-C4alkyl, C1-C3haloalkyl, cyano, halogen, C1-C3alkoxy, C1-C3haloalkoxy; and —C1-C3alkylene-C1-C3alkoxy; and wherein the C3-C10alkyl, C3-C10alkenyl, C3-C10alkynyl, C3-C10haloalkyl, C3-C10haloalkenyl, and C3-C10haloalkynyl are optionally substituted with a substituent selected from the group consisting of COOR10′, CONR10′R11′, CH2OR10′, SO3R10′, SO2NR10′R11′, PO(OR10′)2, and tetrazol-5-yl; R10′ is H, C1-C4 alkyl, or aryl; R11′ is H, C1-C4 alkyl, COR12′, OR10′, or SO2R12′; R12′ is C1-C4 alkyl; L3 is C1-C6alkylene, C2-C6alkenylene, C2-C6alkynylene, —(CH2)m-G3-(CH2)q—, —(CH2)m-G4 (CH2)q—, or -G5-C≡C—; wherein the C1-C6alkylene, C2-C6alkenylene, and C2-C6alkynylene are optionally substituted with 1, 2, 3, or 4 fluoro substituents; and wherein m and q are each independently 0, 1, 2, or 3 and m+q=0, 1, 2, 3, or 4; G3 is O, C(O), S, S(O), S(O)2, or NR9; wherein R9 is H, C1-C4 alkyl, or C1-C4alkylcarbonyl; G4 iswherein G4 is optionally substituted with 1, 2, or 3 substituents selected from the group consisting of C1-C4alkyl, C1-C3haloalkyl, cyano, halogen, C1-C3alkoxy, and C1-C3haloalkoxy; G5 iswherein G5 is optionally substituted with 1, 2, or 3 substituents selected from the group consisting of C1-C4alkyl, C1-C3haloalkyl, cyano, halogen, C1-C3alkoxy, and C1-C3haloalkoxy; R7 is C3-C8cycloalkyl, aryl, heteroaryl, or heterocyclyl; wherein R7 is optionally substituted with 1, 2, 3, or 4 substituents selected from the group consisting of C1-C4alkyl, C1-C3haloalkyl, cyano, halogen, C1-C3alkoxy, C1-C3haloalkoxy, and —C1-C3alkylene-C1-C3alkoxy; r is 0 or 1; and s is 0 or 1.
地址 Ann Arbor MI US